vimarsana.com
Home
Live Updates
Aeglea BioTherapeutics Announces Interim Results from Ongoin
Aeglea BioTherapeutics Announces Interim Results from Ongoin
Aeglea BioTherapeutics Announces Interim Results from Ongoing Phase 1/2 Clinical Trial of Pegtarviliase for the Treatment of Classical Homocystinuria and Begins Process to Explore Strategic Alternatives
Results from Cohorts 1 and 2 Showed a Dose-Dependent Reduction in Total Homocysteine Levels
Results from Cohort 3 Indicated Additional Dose Exploration and Data from Longer Treatment Duration May... | April 12, 2023
Related Keywords
Texas ,
United States ,
Linda Neuman ,
Aeglea Biotherapeutics ,
Jeffrey Goldberg ,
Cortney Caudill ,
Michaelc Hanley ,
Aeglea Biotherapeutics Inc ,
Exchange Commission ,
Wedbush Securities Inc ,
Company Annual Report On Form ,
Nasdaq ,
European Medicines Agency ,
Dose Dependent Reduction ,
Total Homocysteine Levels ,
Additional Dose Exploration ,
Longer Treatment Duration May ,
Percent Change ,
Total Homocysteine ,
Baseline After ,
Post Dose ,
Explore Strategic ,
Wedbush Securities ,
Middle East ,
Immedica Pharma ,
Marketing Authorization Application ,
Classical Homocystinuria ,
Drug Designation ,
Pediatric Disease ,
Fast Track ,
European Medicines ,
Securities Litigation Reform Act ,
Annual Report ,
United States Securities ,
Nc Stock Exchange ,
News ,
Information ,
Press Release ,
Results ,
Rom ,
Cohorts ,
,
End ,
Howed ,
Reduction ,
N ,
Total ,
Homocysteine ,
Levels ,
Cohort ,
Syndicated ,
Dditional ,
Nose ,
Exploration ,
Data ,
Longer ,
Treatment ,
Uration Agle Us00773j1034 ,